Company Number: 14737098

Analysis Date: 2025-07-29 13:32 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Veripharm Ltd is a newly incorporated private limited company (March 2023) operating in a professional, scientific, and technical sector (SIC 74909). The first set of accounts to 31 March 2024 shows a modest but positive net asset position and working capital surplus. However, the company is still in its infancy with limited operating history and scale, which presents uncertainty on stable future cash flows and profitability. The presence of director loans (£25,202) as a significant current liability indicates reliance on internal funding which may constrain liquidity in a downturn. Conditional approval is recommended with a requirement for ongoing review of trading performance, cash flow generation, and repayment of director loans.

2. Financial Strength:

• Net Assets: £13,316 positive equity base.
• Fixed Assets minimal (£277) indicating asset-light operations.
• Net Current Assets: £13,039 (Current Assets £46,831 minus Current Liabilities £33,792).
• Current Liabilities predominantly director loans (£25,202) and tax liabilities (£7,750), suggesting short-term obligations to related parties and tax authorities.
  The balance sheet shows a sound equity base relative to liabilities, but the material director loan increases financial leverage and potential risk if external funding is needed.

3. Cash Flow Assessment:

• Cash at bank £41,203 provides reasonable liquidity buffer for current operations.
• Debtors £5,628 suggests some customer receivables but not significant.
• Current liabilities due within one year include tax and director loans totaling nearly £33,000, which must be managed carefully.
• The company employs only one person and is currently exempt from audit, limiting financial transparency.
  Overall liquidity is adequate currently, but the reliance on director loans for funding indicates tight working capital management and potential vulnerability if trading conditions worsen.

4. Monitoring Points:

• Track director loan balances and repayment plans to assess leverage and potential cashflow risk.
• Monitor trading turnover and profitability trends to confirm viability beyond start-up phase.
• Watch tax liabilities to ensure no accumulation of overdue debts.
• Review subsequent filings for evidence of cash flow improvement and reduction of current liabilities.
• Assess any changes in management or business strategy that could impact risk profile.